TREATMENT OF MEDICATION-RELATED OSTEONECROSIS OF THE JAW USING BICHAT‘S BUCCAL FAT PAD: A CASE REPORT

Medication-related osteonecrosis of the jaw (MRONJ) is a multifactorial pathology, and it occurs in response to modification of bone remodeling during systemic antiresorptive therapy (eg, drugs such as denosumab). MRONJ is defined by a persistent necrotic bone (more than 8 weeks), which may be assoc...

Full description

Saved in:

Bibliographic Details
Published in:	Oral surgery, oral medicine, oral pathology and oral radiology Vol. 130; no. 3; p. e190
Main Authors:	SILVA, CLÁUDIA REBECCA COSTA CAVALCANTE, JÚNIOR, MANUEL LIBERATO DE LUCENA, FREIRE, MATHEUS CRISTINO, PANJWANI, CAMILA MARIA BEDER RIBEIRO GIRISH, SALMOS-BRITO, JANAINA ANDRADE LIMA, BESSA-NOGUEIRA, RICARDO VIANA
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 01-09-2020
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Medication-related osteonecrosis of the jaw (MRONJ) is a multifactorial pathology, and it occurs in response to modification of bone remodeling during systemic antiresorptive therapy (eg, drugs such as denosumab). MRONJ is defined by a persistent necrotic bone (more than 8 weeks), which may be associated with edema, erythema, and pain. Treatment objectives are to eliminate pain, control infection (soft and hard tissue), and minimize the progression or occurrence of necrosis. This study aimed to report the case of a 53-year-old Latin American woman who complained of unpleasant odor and taste associated with the posterior maxillary region (tooth n18). She was using denosumab because of breast cancer, which progressed with bone metastasis. The tooth and adjacent bone were surgically removed, and histopathologic examination revealed bone necrosis (stage 3). During the procedure, the oroantral communication was treated with Bichat’s buccal fat pad. During the follow-up, no pain nor recurrence was reported.
ISSN:	2212-4403 2212-4411
DOI:	10.1016/j.oooo.2020.04.380